You are here:

  1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Blood and immune system conditions
  5. Lymphoedema

L-Dex U400 for lymphoedema after breast cancer treatment

  • Medtech innovation briefing
  • Reference number: MIB111
  • Published:  04 July 2017

Download (PDF)
  • Overview
  • Summary
  • The technology
  • Regulatory information
  • Equality considerations
  • Clinical and technical evidence
  • Specialist commentator comments
  • Specialist commentators
  • Development of this briefing

Overview

NICE has developed a medtech innovation briefing (MIB) on L-Dex U400 for lymphoedema after breast cancer treatment.

What are MIBs?


Next page Summary
Back to top